AUTHORS
Na Xu, Sai Ma2, Long Chang3, Chunyan Chen4, Hao Cai5, Wenqi Zheng6, Tingting Cui7, Daoxiang WU, MA8, Sujiang Zhang, MD9, Minghui Duan, MD10
AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Qilu Hospital of Shandong University, Jinan, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Qilu Hospital of Shandong University, Jinan, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Department of Hematology, Beijing No.6 Hospital, Beijing, China
7 Department of Hematology, Beijing No.6 Hospital, Beijing, China
8 PharmaEssentia Biotech (Beijing) Limited, Beijing, China
9 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
ABSTRACT
Introduction
Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem-cell disorders characterized by constitutive JAK–STAT pathway activation, excessive myeloproliferation, thromboembolic risk, myelofibrotic progression, and leukemic transformation. Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon with a single positional isomer, providing sustained pharmacologic exposure and favorable tolerability. In China mainland, ropeginterferon alfa-2b has been approved for polycythemia vera (PV) with an escalating dose regimen of 250 μg, 350 μg, and 500 μg. Prior clinical experience in chronic hepatitis showed that high upfront doses of ropeginterferon alfa-2b, including 450 μg every 2 weeks, were clinically manageable. Together with the availability of a 500 μg formulation in China, these data provide the rationale for evaluating a toxicity-guided dose de-escalation strategy initiated at 500 μg in patients with MPNs.
Objective
This study evaluated the safety and efficacy of ropeginterferon alfa-2b initiated at 500 μg followed by toxicity-guided dose de-escalation in patients with MPNs.
Methods
This multicenter retrospective study included patients with MPNs who received ropeginterferon alfa-2b at four hospitals between March 1, 2025, and February 28, 2026. All patients were treated with a 500 μg starting dose followed by toxicity-guided dose modification. Safety assessments included treatment-emergent adverse events (TEAEs) at 6 months, graded according to CTCAE v5.0, and monthly patient-reported quality of life using the EORTC QLQ-C30 questionnaire. Secondary endpoints included complete hematologic response (CHR) at month 3 and 6 and molecular response (MR) at month 6.
Results
A total of 64 patients were included, with a median age of 50 years (range, 10-77), including 21 males (32.8%) and 43 females (67.2%). All patients completed at least 6 months of treatment. Diagnoses included PV in 38 patients, ET in 16, myelofibrosis in 9, and MPN-U in 1. JAK2-only mutations were detected in 50 patients (78.1%), CALR-only mutations in 10 (15.6%), concurrent JAK2 and CALR mutations in 1 (1.6%), and triple-negative status in 3 (4.7%). Nineteen patients (29.7%) were treatment-naïve, and 45 (70.3%) had received prior therapy. Ropeginterferon alfa-2b was administered every 2 weeks in 35 patients (54.7%), every 4 weeks or monthly in 27 patients (42.2%), and every 3 weeks in 2 patients (3.1%).
After adjustment for baseline abnormalities, TEAEs occurred in 40 patients (62.5%) at month 6. Grade ≥3 TEAEs occurred only in 3 patients (4.7%); all were considered possibly treatment-related. No grade 4 or 5 TEAEs were reported. The most common TEAEs were alanine aminotransferase increased (43.8%), aspartate aminotransferase increased (40.6%), lymphocyte count decreased (40.6%), white blood cell count decreased (39.1%), and gamma-glutamyltransferase increased (31.2%). Among 25 evaluable patients with at least four evaluable assessments, the mean EORTC QLQ-C30 score increased from 68.3 at baseline to 73.3 at month 6, with 88.0% of patients showing stable or improved scores over time (QoL scale, 1 [very poor]-100 [excellent]).
Based on the ELN 2013 response criteria, CHR was achieved at month 3 in 78.9% (30/38) of patients with PV, 87.5% (14/16) with ET, and 33.3% (3/9) with MF. At month 6, the corresponding CHR rates were 84.2% (32/38), 87.5% (14/16), and 44.4% (4/9), respectively. Among 41 JAK2-mutated patients with paired baseline and month 6 variant allele frequency (VAF) data available, according to the 2009 ELN criteria, 2 patients (4.9%) achieved complete molecular response (CMR) and 8 of 23 patients with a baseline JAK2 VAF >10% achieved partial molecular response (PMR; 34.8%). By 2013 ELN criteria, 6 of 20 evaluable patients achieved MR (30.0%), including 2 with CMR and 4 with PMR.
Conclusions
In this multicenter retrospective cohort, ropeginterferon alfa-2b initiated at 500 μg followed by toxicity-guided dose de-escalation was feasible and generally well tolerated in MPNs. TEAEs were clinically manageable (mostly mild or moderate) and did not reveal unexpected safety concerns. The regimen was associated with high CHR rates in PV and ET, together with early MR in a subset of patients with JAK2-mutated MPN. These findings support further prospective evaluation of this dosing strategy in MPNs.
DISCLOSURES
Na Xu: No relevant conflicts of interest to declare.